Merck & Co said it is planning to submit regulatory applications for letermovir in the US and European Union sometime this year, on the back of late-stage data showing its promise in preventing a serious viral infection in patients undergoing a bone marrow transplant.
MAKE IT MODERN
The European Commission has issued a conditional green light for Johnson & Johnson's planned $30 billion purchase of Actelion, laying out the commitments it feels are necessary to ensure that clinical development of the firms' innovative insomnia drugs will not be adversely affected by the merger.
The US Food and Drug Administration will undertake a priority review of Bristol-Myers Squibb’s immunotherapy Opdivo as a treatment for patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC).
Sanofi has pulled the plug on its experimental Clostridium difficile vaccine after an interim analysis of a late-stage trial concluded that key targets were unlikely to be met.
Amgen’s Blincyto has been issued a full approval in the US as a treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
New analysis highlights that Scotland’s pharmaceutical industry “can be a driving force” for long-term sustainable economic growth, says the Association of the British Pharmaceutical Industry Scotland.
AstraZeneca and US biopharma Berg have entered a research pact to identify and evaluate novel targets and therapeutics to treat neurological disorders with the help of artificial intelligence. AZ also announced expanded approval in the US of breast cancer drug Faslodex.